Correction: Oral ponesimod in relapsing-remitting multiple sclerosis: A randomised phase II trial(Journal of Neurology, Neurosurgery and Psychiatry DOI: 10.1136/jnnp-2013-307282);Oral ponesimod in relapsing-remitting multiple sclerosis: A randomised phase II trial

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 11, 2014, Pages 1198-1208

  Olsson, Tomas ^a   Boster, Aaron ^b   Fernández, Óscar ^c   Freedman, Mark S ^d   Pozzilli, Carlo ^e   Bach, Doris ^f   Berkani, Ouali ^f   Mueller, Markus S ^f   Sidorenko, Tatiana ^f   Radue, Ernst Wilhelm ^g   Melanson, Maria ^h  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b OHIO STATE UNIVERSITY   (United States)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f ACTELION PHARMACEUTICALS LTD   (Switzerland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PONESIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; THIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECEPTORS, LYSOSPHINGOLIPID; SEVERITY OF ILLNESS INDEX; THIAZOLES; YOUNG ADULT;

EID: 84896421226     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-307282corr1     Document Type: Erratum

References (31)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17.
2. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001;22:117-39.
3. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69-77.
4. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
5. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
6. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303.
7. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107.
8. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
9. Bolli MH, Abele S, Binkert C, et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem 2010;53:4198-211.
10. Piali L, Froidevaux S, Hess P, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 2011;337:547-56.
11. Gatfield J, Nayler O. Ponesimod is a potent S1P1 receptor modulator causing efficient receptor internalisation, degradation and functional antagonism (P926). Multiple Sclerosis Journal 2012;18(Suppl 4):422.
12. Brossard P, Derendorf H, Xu J, et al. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol 2013;76:888-96.
13. Brossard P, Maatouk H, Halabi A, et al. Ascending multiple-dose study with ponesimod, a selective S1P1 receptor agonist: tolerability, safety, pharmacokinetics, and pharmacodynamics (P110). Clin Pharmacol Ther 2012;91(Suppl 1):S93.
14. Reyes M, Brossard P, D'Ambrosio D, et al. Mass balance, pharmacokinetics, and metabolism of the selective oral S1P1 receptor modulator ponesimod in humans. Clin Pharmacol Drug Dev 2012;1:219.
15. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis:2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
16. WMA. World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects, 2008.
17. ICH. Guideline for Good Clinical Practice, 1996.
18. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40.
19. Kappos L, Gold R, Miller DG, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;372:1463-72.
20. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479-89.
21. Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics 2005;61:738-48.
22. Selmaj K, Li DK, Hartnung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised,phase 2 study. Lancet Neurol 2013;12:756-67. http://dx.doi.org/10.1016/S1474-4422(13)70102-9.
23. O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900.
24. Novartis Pharmaceuticals Corporation. Prescribing information: GILENYA (fingolimod) capsules. http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf (accessed 28 Jun 2013).
25. Kovarik JM, Schmouder R, Barilla D, et al. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 2004;44:532-7.
26. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002;277:21453-7.
27. Fryer RM, Muthukumarana A, Harrison PC, et al. The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specifi c bradycardia (S1P1) and hypertension (S1P3) in rat. PLoS ONE 2012;7:e52985.
28. Means CK, Brown JH. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res 2009;82:193-200.
29. Keller CD, Rivera Gil P, Tölle M, et al. Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. Am J Pathol 2007;170:281-92.
30. Sobel K, Menyhart K, Killer N, et al. Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling. J Biol Chem 2013;288:14839-51.
31. Miron VE, Ludwin SK, Darlington PJ, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 2010;176:2682-94.